Luminary Therapeutics Revenue and Competitors
Employee Data
- Luminary Therapeutics has 12 Employees.
- Luminary Therapeutics grew their employee count by 20% last year.
Luminary Therapeutics's People
| Name | Title | Email/Phone |
|---|
Luminary Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.8M | 50 | 9% | N/A | N/A |
#2 | $7.4M | 48 | -35% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.3M | 2 | -91% | N/A | N/A |
#5 | $3.6M | 23 | 5% | N/A | N/A |
#6 | $0.9M | 6 | -33% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $14.7M | 95 | 9% | N/A | N/A |
#9 | $14.7M | 95 | 0% | $20.5M | N/A |
#10 | $27.9M | 144 | 13% | $39.1M | N/A |
What Is Luminary Therapeutics?
Luminary is a clinical stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and or TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique are that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T-Cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with 3 antigen receptors specifically designed to overcome antigen escape.\n\n\nFor more information visit www.luminarytx.com\n\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less
keywords:N/A
N/A
Total Funding
12
Number of Employees
N/A
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Minneapolis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 12 | -25% | N/A |
#2 | $0.4M | 12 | 0% | $3.9M |
#3 | $1M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |